The National Institute of Health and Clinical Excellence (NICE) has published new guidance for the month of July 2012. This month there are two technology appraisals that impact upon primary care.
The adalimumab (Humira®) for the treatment of moderate to severe ulcerative colitis appraisal has been terminated and the treatment cannot be recommended. No evidence submission was made by the manufacturer or technology sponsor.
Rivaroxaban (Xarelto®) is recommended as an option for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism. This treatment was evaluated against warfarin and low molecular weight heparins (LMWH). It is noted that in the short term this treatment is less expensive than other options. Over longer periods it becomes more expensive but the additional expense is justified by additional benefits in terms of less monitoring compared to warfarin and oral route of administration compared to LMWH.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.